Proposal to list desmopressin tablets, progesterone capsules and mesalazine granules
PHARMAC is seeking feedback on a proposal for listings in Section B and Part II of Section H of the Pharmaceutical Schedule through a provisional agreement with Pharmaco (NZ) Ltd.
In summary, this proposal would result in:
- Desmopressin tablets being funded, subject to Special Authority restrictions, for patients who have primary nocturnal enuresis or cranial diabetes insipidus and where the subsidised nasal preparations are contraindicated and (in the case of nocturnal enuresis) an enuresis alarm cannot be used;
- Progesterone capsules being funded, subject to Special Authority restrictions, for the prevention of pre-term labour where the patient has a short cervix or has a history of pre-term birth; and
- Mesalazine granules being funded, under Special Authority restrictions, for patients who are under the age of 16 and unable to swallow tablets.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 28 June 2013 to:
Therapeutic Group Manager
PO Box 10 254
Fax: 04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.